MARKET

IMMX

IMMX

Immix Biopharma Inc
NASDAQ
5.56
-0.38
-6.40%
After Hours: 5.42 -0.14 -2.60% 19:58 12/17 EST
OPEN
6.00
PREV CLOSE
5.94
HIGH
6.16
LOW
5.33
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
7.73
52 WEEK LOW
1.340
MARKET CAP
289.97M
P/E (TTM)
-7.1816
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMMX last week (1208-1212)?
Weekly Report · 2d ago
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition
Seeking Alpha · 12/11 05:10
Immix Biopharma CEO Ilya Rachman Acquires Common Shares
Reuters · 12/10 23:49
Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares
Reuters · 12/10 23:47
IMMIX BIOPHARMA ANNOUNCES CLOSING OF UPSIZED $100 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
Reuters · 12/09 22:45
Immix Biopharma Price Target Raised to $12.00/Share From $8.00 by HC Wainwright & Co.
Dow Jones · 12/09 15:42
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/09 15:42
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $12
Benzinga · 12/09 15:32
More
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.